In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans

@article{Pfaller2001InVA,
  title={In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. andCryptococcus neoformans},
  author={Michael A. Pfaller and Shawn A. Messer and Richard J. Hollis and Ronald Jones},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2001},
  volume={45},
  pages={2862 - 2864}
}
ABSTRACT Posaconazole is a new investigational triazole with broad-spectrum antifungal activity. The in vitro activities of posaconazole were compared with those of itraconazole and fluconazole against 3,685 isolates of Candida spp. (3,312 isolates) and C. neoformans (373 isolates) obtained from over 70 different medical centers worldwide. The MICs of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards… Expand
In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts
TLDR
Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was frequently more active than other azoles and amphotericin B. Expand
In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp
TLDR
R ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazoles against all Candida spp. Expand
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
TLDR
Both voriconazole and posaconazole were more active than fluconazole against all Candida spp. Expand
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
TLDR
Both posaconazole and ravuconazole showed similar broad-spectrum activity against dermatophyte, yeast and non-dermatophyte species and were compared with three well-established antifungal agents against 184 clinical isolates. Expand
Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi
TLDR
Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species. Expand
Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E‐test methods
TLDR
E‐test showed good correlation with the CLSI method, but to facilitate the comparability of results the authors believe that DMSO should be used as solvent in the BMD. Expand
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
The in vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and C . gattii to five antifungal drugs (amphotericin B, flucytosine, fluconazole, itraconazole andExpand
In Vitro Antifungal Activities of Amphotericin B, Fluconazole, Itraconazole, Terbinafine, Caspofungin, Voriconazole, and Posaconazole against 30 Clinical Isolates of Cryptococcus neoformans var. neoformancs
TLDR
It is concluded that in vitro resistance to antifungal agents has not significantly changed despite the recent wide-spread use of triazoles for long-term treatment of Cryptococcal meningitis. Expand
Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Cryptococcus diffluens is a recently re-established species that shares several phenotypic features with Cryptococcus neoformans. We evaluated the application of the Clinical Laboratory StandardsExpand
The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood.
TLDR
Resistance is still uncommon in non-albicans Candida species recovered from blood cultures, however, in fungaemias caused by C. tropicalis, Candida glabrata and Candida krusei, there is a high prevalence of resistance to fluconazole and flucytosine. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
TLDR
It is suggested that BMS-207147, Sch 56592, and voriconazole all possess promising antifungal activity and that further in vitro and in vivo investigations are warranted to establish the clinical value of this improved potency. Expand
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
TLDR
In vitro susceptibility testing against clinical isolates of Candida spp. Expand
In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens
TLDR
In vitro data suggest that the new antifungal triazole SCH has significant potential for clinical development and is considerably more active than FLC and slightly moreactive than either ITC and KETO. Expand
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
TLDR
The NCCLS standard reference method can be applied without modification to the testing of SCH56592 and itraconazole, but particular attention to solubilizing the agents is critical to obtaining consistent results. Expand
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
TLDR
SCH56592 has potent in vitro activity against C. neoformans and compares favorably to treatment with fluconazole for a central nervous system infection and should be studied for use in humans with cryptococcal infections. Expand
Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts
TLDR
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined. Expand
Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia
TLDR
In summary, POC at ≥6 mg/kg/day per os generated sustained concentrations in plasma of ≥1 μg/ml that were as effective in the treatment and prevention of invasive pulmonary aspergillosis as AMB at 1 mg/ kg/day and more effective than cyclodextrin ITC at ≥ 6 mg/kerpine per os in persistently neutropenic rabbits. Expand
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora
  • J. Rex, M. Pfaller, +8 authors A. Barry
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
TLDR
The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections. Expand
Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys
TLDR
Concentrations above the MICs and minimum fungicidal concentrations for most organisms were observed at 24 h following a single oral dose in MC suspension in all five species studied, suggesting that once-daily administration of SCH 56592 in human subjects would be a therapeutically effective dosage regimen. Expand
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
TLDR
An eight-laboratory collaborative study was carried out to document reproducibility of tests of Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 by the NCCLS method. Expand
...
1
2
...